BILLEV PHARMA ApS: Financial statements 2015
CVR: 81814813
BILLEV PHARMA ApS (CVR 81814813) has filed annual accounts for 2015. In 2015, the company reported a gross profit of DKK 9,747,345 and a net result of DKK 636,436 compared with DKK 516,674 the year before. That is an increase of 0.2% compared with the year before. Equity amounted to DKK 956,436. The solvency ratio was 30.8%.
- Gross Profit
- 9,747,345 kr.
- Profit/Loss
- 636,436 kr.
- Equity
- 956,436 kr.
- Total Assets
- 3,107,218 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2015 | - | 9.7 mio. | 636 t. | 956 t. | - |
| 2014 | - | 9.7 mio. | 517 t. | 1.5 mio. | - |
| 2013 | - | 9.4 mio. | 728 t. | 2.4 mio. | - |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2015
As of April 30, 2015, Ulrikke Lynge Jensen is registered as director of BILLEV PHARMA ApS.
As of April 30, 2015, Anja Wencke van Arkens is registered as director of BILLEV PHARMA ApS.
As of April 30, 2015, Peter de Mayo Billev has stepped down as director of BILLEV PHARMA ApS.
About BILLEV PHARMA ApS
BILLEV PHARMA ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 1977. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Ulrikke Lynge Jensen and Anja Wencke van Arkens. The company is owned by VAN ARKENS HOLDING ApS and UL JENSEN HOLDING ApS. The company has 15 employees. In 2026, the company reported a gross profit of DKK 38,801,270 and a net result of DKK 10,205,639 compared with DKK 6,143,854 the year before. Equity amounted to DKK 10,525,639.
